Company intelligence / Profile preview
Genaera Corporation
Plymouth Meeting, Pennsylvania, USAgenaera.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
Genaera Corporation was a biopharmaceutical company that developed several drug candidates, with its lead product trodusquemine (MSI-1436) for type 2 diabetes and obesity, and EVIZON (squalamine lactate) for wet age-related macular degeneration. The company's highest clinical achievement was reaching Phase 3 with Pexiganan Acetate for diabetic foot. The company's Board of Directors approved a Plan of Complete Liquidation and Dissolution in April 2009.
- Therapeutic areas
- PulmonologyOphthalmologyEndocrinologyOtherInfectious Diseases
- Modalities
- Small molecule drugsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
MedImmune, Inc. (for asthma treatment in Phase 2 clinical testing)DepYmed, Inc.
Beyond the preview
Go deeper on Genaera Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genaera Corporation.